ESTETHIS STUDY IS DESIGNED TO COMPARE THE BLOOD PRESSURE LOWERING EFFICACY OF ALISKIREN, A COMBINATION OF ALISKIREN PLUS AMLODIPINE, AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE HYPERTENSION. IT WILL ALSO COMPARE THE LONG-TERM SAFETY OF AN ALISKIREN-BASED REGIMEN TO A RAMIPRIL-BASED REGIME

计划入组 0 人

Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)

计划入组 441 人 · 首次发布于 2019 年 2 月 28 日

Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR

计划入组 100 人 · 首次发布于 2026 年 1 月 27 日

IPR-456

IDR-1018

INR-302

IPR Pharmaceuticals, Inc.

Puerto Rico

Isr Immune System Regulation AB

Sweden

CBRE Clarion Global Real Estate Income Fund

Gut Metabolite Imidazole Propionate Identified as Novel Atherosclerosis Driver and Therapeutic Target

Philips Launches DEFINE GPS Trial to Evaluate iFR-Guided PCI for Superior Outcomes

VectorBuilder Launches MuteFree AAV Technology to Solve ITR Instability in Gene Therapy Manufacturing